Novel helix-constrained nociceptin derivatives are potent agonists and antagonists of ERK phosphorylation and thermal analgesia in mice

Journal of Medicinal Chemistry

Volumn 53, Issue 23, 2010, Pages 8400-8408

  Harrison, Rosemary S ^a   Ruiz Gómez, Gloria ^a   Hill, Timothy A ^a   Chow, Shiao Y ^a   Shepherd, Nicholas E ^a   Lohman, Rink Jan ^a   Abbenante, Giovanni ^a   Hoang, Huy N ^a   Fairlie, David P ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; NOCICEPTIN DERIVATIVE; NOCICEPTIN RECEPTOR AGONIST; NOCICEPTIN RECEPTOR ANTAGONIST;

ALPHA HELIX; AMINO ACID SUBSTITUTION; ANALGESIA; ANALGESIC ACTIVITY; ANIMAL CELL; ANXIETY; ARTICLE; CONTROLLED STUDY; CYCLIZATION; DRUG POTENCY; ENZYME PHOSPHORYLATION; FOOD INTAKE; HUMAN; HUMAN CELL; IMMUNITY; LEARNING; LOCOMOTION; MALE; MEMORY; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PAIN; PROTON NUCLEAR MAGNETIC RESONANCE;

AMINO ACID SEQUENCE; ANALGESICS; ANIMALS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OPIOID PEPTIDES; PHOSPHORYLATION; TEMPERATURE;

EID: 78649901086     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101139f     Document Type: Article

References (49)

1. Meunier, J. C.; Mollereau, C.; Toll, L.; Suaudeau, C.; Moisand, C.; Alvinerie, P.; Butour, J. L.; Guillemot, J. C.; Ferrara, P.; Monsarrat, B.; Mazarguil, H.; Vassart, G.; Parmentier, M.; Costentin, J. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor Nature 1995, 377, 532-535
2. Chiou, L. C.; Liao, Y.-Y.; Fan, P. C.; Kuo, P.-H.; Wang, C.-H.; Riemer, C.; Prinssen, E. P Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications Curr. Drug. Targets 2007, 8, 117-135
3. Lambert, D. G. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential Nat. Rev. 2008, 7, 694-710
4. Mustazza, C.; Bastanzio, G. Development of nociceptin receptor (NOP) agonists and antagonists. Med. Res. Rev. [Online early access]. DOI: 10.1002/med.20197. Published Online: Jan 22, 2010.
5. Largent-Milnes, T. M.; Vanderah, T. W. Recently patented and promising ORL-1 ligands: where have we been and where are we going? Expert Opin. Ther. Pat. 2010, 20, 291-305
6. Mollereau, C.; Mouledous, L. Tissue distribution of the opioid receptor-like (ORL1) receptor Peptides 2000, 21, 907-917
7. Halford, W. P.; Gebhardt, B. M.; Carr, D. J. Functional role and sequence analysis of a lymphocyte orphan opioid receptor J. Neuroimmunol. 1995, 59, 91-101
8. Wick, M. J.; Minnerath, S. R.; Roy, S.; Ramakrishnan, S.; Loh, H. H. Expression of alternate forms of brain opioid "orphan" receptor mRNA in activated human peripheral blood lymphocytes and lymphocytic cell lines Mol. Brain Res. 1995, 32, 342-347
9. Peluso, J.; LaForge, K. S.; Matthes, H. W.; Kreek, M. J.; Kieffer, B. L.; Gavériaux-Ruff, C. Distribution of nociceptin/orphanin FQ receptor transcript in human central nervous system and immune cells J. Neuroimmunol. 1998, 81, 184-192
10. Peluso, J.; Gavériaux-Ruff, C.; Matthes, H. W.; Filliol, D.; Kieffer, B. L. Orphanin FQ/nociceptin binds to functionally coupled ORL1 receptors on human immune cell lines and alters peripheral blood mononuclear cell proliferation Brain Res. Bull. 2001, 54, 655-660
11. Anton, B.; Leff, P.; Meissler, J. J.; Calva, J. C.; Acevedo, R.; Salazar, A.; Matus, M.; Flores, A.; Martinez, M.; Adler, M. W.; Gaughan, J. P.; Eisenstein, T. K. Nociceptin/orphanin FQ suppresses adaptive immune responses in vivo and at picomolar levels in vitro J. Neuroimmune Pharmacol. 2010, 5, 143-154
12. Hu, E.; Calò, G.; Guerrini, R.; Ko, M. C. Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112 Pain 2010, 148, 107-113
13. Klukovits, A.; Tekes, K.; Gündüz Çinar, Ö.; Benyhe, S.; Borsodi, A.; Deák, B. H.; Hajagos-Tóth, J.; Verli, J.; Falkay, G.; Gáspár, R. Nociceptin inhibits uterine contractions in term-pregnant rats by signaling through multiple pathways Biol. Reprod. 2010, 83, 36-41
14. Murphy, N. P. The nociceptin/orphanin FQ system as a target for treating alcoholism CNS Neurol. Disord.: Drug Targets 2010, 9, 87-93
15. Volta, M.; Marti, M.; McDonald, J.; Molinari, S.; Camarda, V.; Pelà, M.; Trapella, C.; Morari, M. Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6- tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4) Peptides 2010, 31, 1194-1204
16. Mabrouk, O, S; Marti, M.; Morari, M. Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naive and nociceptin/orphanin FQ receptor knockout mice Neuroscience 2010, 166, 40-48
17. Mogil, J. S.; Pasternak, G. W. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family Pharmacol. Rev. 2001, 53, 381-415
18. Ko, M. C.; Naughton, N. N. Antinociceptive Effects of Nociceptin/Orphanin FQ Administered Intrathecally in Monkeys J. Pain 2009, 10, 509-516
19. Reiss, D.; Wichmann, J.; Tekeshima, H.; Kieffer, B. L.; Ouagazzal, A. M. Effects of nociceptin/orphanin FQ receptor (NOP) agonist, Ro64-6198, on reactivity to acute pain in mice: comparison to morphine Eur. J. Pharmacol. 2008, 579, 141-148
20. Sakurada, T.; Komatsu, T.; Moriyama, T.; Sasaki, M.; Sanai, K.; Orito, T.; Sakurada, C.; Sakurada, S. Effects of intraplantar injections of nociceptin and its N-terminal fragments on nociceptive and desensitized responses induced by capsaicin in mice Peptides 2005, 26, 2505-2512
21. 2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor Br. J. Pharmacol. 2002, 136, 303-311
22. King, M. A.; Rossi, G. C.; Chang, A. H.; Williams, L.; Pasternak, G. W. Spinal analgesic activity of orphanin FQ/nociceptin and its fragments Neurosci. Lett. 1997, 223, 113-116
23. Reinscheid, R. K.; Ardati, A.; Monsma, F. J., Jr.; Civelli, O. Structure-activity relationship studies on the novel neuropeptide orphanin FQ J. Biol. Chem. 1996, 271, 14163-14168 (Pubitemid 26191300)
24. 2, a pure and selective nociceptin/orphanin FQ receptor antagonist J. Pept. Res. 2001, 57, 215-222
25. Okada, K.; Sujaku, T.; Chuman, Y.; Nakashima, R.; Nose, T.; Costa, T.; Yamada, Y.; Yokoyama, M.; Nagahisa, A.; Shimohigashi, Y. Highly potent nociceptin analog containing the Arg-Lys triple repeat Biochem. Biophys. Res. Commun. 2000, 278, 493-498
26. McDonald, J.; Calo, G.; Guerrini, R.; Lambert, D. G. UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPgamma(35)S binding studies Naunyn Schmiedeberg's Arch. Pharmacol. 2003, 367, 183-187
27. 2: identification of highly potent agonists of the nociceptin/orphanin FQ receptor J. Med. Chem. 2001, 44, 3956-3964
28. Orsini, M. J.; Nesmelova, I.; Young, H. C.; Hargittai, B.; Beavers, M. P.; Liu, J.; Connolly, P. J.; Middleton, S. A.; Mayo, K. H. The nociceptin pharmacophore site for opioid receptor binding derived from the NMR structure and bioactivity relationships J. Biol. Chem. 2005, 280, 8134-8142
29. Chang, M.; Peng, Y. L.; Dong, S. L.; Han, R. W.; Li, W.; Yang, D. J.; Chen, Q.; Wang, R. Structure-activity studies on different modifications of nociceptin/orphanin FQ: identification of highly potent agonists and antagonists of its receptor Regul. Pept. 2005, 130, 116-122
30. Ambo, A.; Hamazaki, N.; Yamada, Y.; Nakata, E.; Sasaki, Y. Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfidecontaining analogues of nociceptin peptides J. Med. Chem. 2001, 44, 4015-4018
31. Charoenchai, L.; Wang, H.; Wang, J. B.; Aldrich, J. V. High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues J. Med. Chem. 2008, 51, 4385-4387
32. Shepherd, N. E.; Hoang, H. N.; Abbenante, G.; Fairlie, D. P. Single turn alpha helical peptides with exceptional stability in water J. Am. Chem. Soc. 2005, 127, 2974-2983
33. Shepherd, N. E.; Abbenante, G.; Fairlie, D. P. Consecutive cyclic pentapeptide modules form short α-helices that are very stable to water and denaturants Angew. Chem., Int. Ed. 2004, 43, 2687-2690
34. Shepherd, N. E.; Hoang, H. N.; Desai, V. S.; Letouze, E.; Young, P. R.; Fairlie., D. P. Modular alpha helical mimetics with antiviral activity against respiratory syncitial virus J. Am. Chem. Soc. 2006, 128, 13284-13289
35. Harrison, R. S.; Shepherd, N. E.; Hoang, H. N.; Ruiz-Gómez, G.; Hill, T. A.; Driver, R. W.; Desai, V. S.; Young, P. R.; Abbenante, G.; Fairlie, D. P. Downsizing human, bacterial, and viral proteins to short water-stable alpha helices that maintain biological potency Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 11686-11691
36. Klaudel, L.; Legowska, A.; Brzozowski, K.; Silberring, J.; Wojcik, J. Solution conformational study of nociceptin and its 1-13 and 1-11 fragments using circular dichroism and two-dimensional NMR in conjunction with theoretical conformational analysis J. Pept. Sci. 2004, 10, 678-690
37. Tyndall, J. D. A.; Pfeiffer, B.; Abbenante, G.; Fairlie, D. P. Over 100 peptide-activated G protein-coupled receptors recognize ligands with turn structure Chem. Rev. 2005, 105, 793-826
38. Ruiz-Gómez, G.; Tyndall, J. D. A.; Pfeiffer, B.; Abbenante, G.; Fairlie, D. P. Update 1 of: Over 100 peptide-activated G protein-coupled receptors recognize ligands with turn structure Chem. Rev. 2010, 110, PR1-PR41
39. 2+ in the SH-SY5Y human neuroblastoma cell line Br. J. Pharmacol. 1996, 118, 205-207
40. Wang, W.; Cui, Q.; Li, Y.; Li, B.; Yang, X.; Cui, L.; Jin, H.; Qu, L. The role of ERK-1/2 in the N/OFQ-induced inhibition of delayed rectifierpotassium currents Biochem. Biophys. Res. Commun. 2010, 394, 1058-1062
41. Guerrini, R.; Caló, G.; Lambert, D. G.; Carrá, G.; Arduin, M.; Barnes, T. A.; McDonald, J.; Rizzi, D.; Trapella, C.; Marzola, E.; Rowbotham, D. J.; Regoli, D.; Salvadori, S. N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands J. Med. Chem. 2005, 48, 1421-1427
42. Calo, G.; Guerrini, R.; Rizzi, A.; Salvadori, S.; Burmeister, M.; Kapusta, D. R.; Lambert, D. G.; Regoli, D. UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor CNS Drug Rev. 2005, 11, 97-112
43. Lapalu, S.; Moisand, C.; Butour, J. L.; Mollereau, C.; Meunier, J. C. Different domains of the ORL1 and kappa-opioid receptors are involved in recognition of nociceptin and dynorphin A FEBS Lett. 1998, 427, 296-300
44. Topham, C. M.; Moulédous, L.; Poda, G.; Maigret, B.; Meunier, J. C. Molecular modelling of the ORL1 receptor and its complex with nociceptin Protein Eng. 1998, 11, 1163-1179
45. Guerrini, R.; Caló, G.; Bigoni, R.; Rizzi, A.; Varani, K.; Toth, G.; Gessi, S.; Hashiba, E.; Hashimoto, Y.; Lambert, D. G.; Borea, P. A.; Tomatis, R.; Salvadori, S.; Regoli, D. Further studies on nociceptin-related peptides: discovery of a new chemical template with antagonist activity on the nociceptin receptor J. Med. Chem. 2000, 43, 2805-2813
46. Fairlie, D. P.; West, M. W.; Wong, A. K. Towards protein surface mimetics Curr. Med. Chem. 1998, 5, 29-62
47. Wider, G.; Dreier, L. Measuring protein concentrations by NMR spectroscopy J. Am. Chem. Soc. 2006, 128, 2571-2576
48. Liu, M.; Mao, X.-a.; Ye, C.; Huang, H.; Nicholson, J. K.; Lindon, J. C. Improved WATERGATE pulse sequences for solvent suppression in NMR spectroscopy J. Magn. Reson. 1998, 132, 125-129
49. Brunger, A. T. Xplor 3.851; Yale University: New Haven, CT, 1992.